Navigation Links
Gemzar the New Drug for Recurrent Ovarian Cancer

The FDA has approved Gemzar for the treatment of recurrent ovarian cancer ignoring the advice of the FDA panel.//

It said that Gemzar in combination with carboplatin (chemotherapy) is very effective for women with advanced ovarian cancer. The drug Gemzar also known by its generic name gemcitabine and was approved after the company provided with additional information to the FDA. According to the statistics of the American Cancer Society about 22,000 women are diagnosed with the disease and 16,000 women die each year. The problem with ovarian cancer is that the tumor tends to recur, making the treatment difficult and resulting in low survival rates.

Gemzar is already approved in the US for lung, pancreatic and breast cancers. In the clinical trails it was found that ovarian cancer patients taking Gemzar with carboplatin had increased progression-free survival rates than patients taking carboplatin alone. The FDA advisory panel voted against recommending the drug when the panel members were concerned that patients in the trial did not survive longer than those taking carboplatin alone. But the company replied that their aim is to prevent the cancer from worsening and not to help patients live longer. The treatment with Gemzar costs about $12,600 which does not increase the longevity of the patient but allows them to have less frequent chemotherapy.


'"/>




Page: 1

Related medicine news :

1. Estrogen Does Not Prevent Recurrent Strokes
2. Radiation Therapy An Effective Solution For Recurrent Prostate Cancer
3. Prevention Of Recurrent Leg Ulcers
4. Measuring Urinary Protein Helps In Detecting Recurrent Bladder Cancer
5. Sertraline Can Prevent Recurrent Depressive Episodes In Diabetics
6. Angola Warned of Recurrent Cholera Outbreaks
7. Recurrent Stroke Risk is Minimized by Statin
8. Blood Markers Predict Risk for Recurrent Stroke and Mortality
9. Targeted Compound Helps Recurrent Prostate Cancer Patients
10. Ancient Indian Herb May Prove Cure For Recurrent UTI
11. Ovarian cancer in relationship with Hormone therapy
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/20/2017)... ... February 20, 2017 , ... ... to purchase a new ultrasound-enhanced thrombolysis machine, a state-of-the-art device that breaks up ... facilitated by the Pepin Family Foundation. , “We greatly appreciate this gift from ...
(Date:2/19/2017)... ... February 19, 2017 , ... Orbita, ... join forces with Healthwise ® at HIMSS 2017 to showcase ... in evidence-based health education, technology and services, will demonstrate a voice-powered knowedge assistant ...
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter President, Joette ... the Pet Life Radio network. The episode, which was posted this week, features ... what factors led to Park Cities Pet Sitter’s being awarded the 2017 National Association ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... foundational and sustainable systems change designed to further positively impact the health and ... of Trustees has long considered it our duty to seriously consider releasing our ...
(Date:2/17/2017)... ... February 17, 2017 , ... Corrective Action ... Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 p.m. ... action (CA) and preventive action (PA)? , The methods share techniques and tools ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... , February 20, 2017 According to a new ... Suspension, Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, ... by MarketsandMarkets, The market is projected to reach USD 52.37 Billion by ... during the forecast period. Continue Reading ... ...
(Date:2/20/2017)...   Alberty   Drugs , a ... has announced a significant shift in focus by ... to servicing local Veteran Affairs Centers (VA) and other ... increased need to secure cost effective treatments for their ... for their goods & services. "The opportunity ...
(Date:2/20/2017)... , February 20, 2017 Acute, Chronic and ... expected to grow at a CAGR of 7% from 2016-2021 and CAGR ... CAGR of 6% from 2016 to 2027. The market is estimated at ... ... Read on to discover how you can exploit the future business opportunities ...
Breaking Medicine Technology: